GlassScriptPhysician profile
Jonathan Pierce Walgama
NPI 1477846871
$1,040.44
in general payments reported to CMS, 2019-2025
11 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2021: $177 · 2022: $260 · 2023: $167 · 2024: $141 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $434.59 | 2019-2024 | Tecnis Simplicity, Tecnis Iol, Whitestar Signature |
| Rxsight INC | $220.86 | 2021-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Alcon Vision LLC | $145.09 | 2021-2023 | Hydrus Microstent |
| Ivantis, INC | $61.70 | 2019 | |
| Glaukos Corporation | $34.17 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $29.72 | 2025 | Eylea, Eylea Hd |
| New World Medical,INC. | $27.16 | 2025 | Ahmed Glaucoma Valve, Streamline, Via360 |
| Rayner Intraocular Lenses Limited | $24.18 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Carl Zeiss Meditec USA, INC. | $22.47 | 2021 | |
| Oyster Point Pharma, INC. | $21.44 | 2023 | Tyrvaya |
| Amgen INC. | $19.06 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Walgama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.